跳到正文
原文
Nature Medicine· Martina L. Porter·· 2026-10-21AI 评分12

作者更正:Povorcitinib 治疗化脓性汗腺炎的 STOP-HS1 和 STOP-HS2 III 期随机双盲安慰剂对照试验

Author Correction: Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials

AI 导读

Nature Medicine 发布更正,修正 Povorcitinib 治疗化脓性汗腺炎 STOP-HS1 和 STOP-HS2 III 期临床试验论文中的数据错误。主要涉及患者基线疾病持续时间范围、STOP-HS2 试验停药人数及原因、P 值上标、生存曲线颜色及 Supplementary Table 6A 的数据列顺序。

正文

Correction to: Nature Medicine https://doi.org/10.1038/s41591-026-04534-z, published online 23 July 2026.

In the version of the article initially published, in the second paragraph of the “Patients” section of the Results, “Baseline disease characteristics were indicative of recalcitrant, longstanding HS (mean (range) disease duration, 9.7 (0.4−49.1)−10.8 (0.3−48.7) years)” should have read “Baseline disease characteristics were indicative of recalcitrant, longstanding HS (mean (range) disease duration, 9.7 (0.4−49.1)−10.8 (0.4−57.7) years)”. In the Fig. 1 legend, in footnote b, “In STOP-HS2, two patients discontinued after completing treatment through week 12: one discontinued due to physician decision, and one withdrew” should have read “In STOP-HS2, three patients discontinued after completing treatment through week 12: two discontinued due to physician decision, and one withdrew”; and footnote d was “Two patients discontinued after completing treatment through week 12; both withdrew” but should have been “One patient withdrew after completing treatment through week 12”. In Table 2, the superscript for the P values in STOP-HS1 for the 75 mg dose in the rows for ≥3-point decrease in Skin Pain NRS and Skin Pain NRS30 should be “f” rather than “e”. In Extended Data Fig. 5e, f, the grey dotted line between weeks 18 and 24 should have been blue and the values next to the week 6 dots should have been next to the week 12 dots. Additionally, in Supplementary Table 6A, the “Week 12” row of the “A75, Baseline A count, 3−5” section originally read “37.2 (16/43), 36.8 (25/68), 35.3 (18/51)” but should have read “36.8 (25/68), 35.3 (18/51), 37.2 (16/43)”. These corrections have been made to the HTML and PDF versions of the article.

Author information

Authors and Affiliations

  1. Department of Dermatology, Harvard Medical School, Boston, MA, USA

    Martina L. Porter

  2. Beth Israel Deaconess Medical Center, Boston, MA, USA

    Martina L. Porter

  3. Inflammatory Diseases Unit, Department of Dermatology, Venereology and Surgery, Hospital de Manises, Valencia, Spain

    Antonio Martorell

  4. Department of Dermatology, University of North Carolina School of Medicine, Chapel Hill, NC, USA

    Christopher J. Sayed

  5. ICH – International Center for Hidradenitis Suppurativa/Acne Inversa, Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, Bochum, Germany

    Falk G. Bechara

  6. Dr. Philip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miami, FL, USA

    Hadar Lev-Tov

  7. Department of Dermatology, University of Southern California, Los Angeles, CA, USA

    Jennifer L. Hsiao

  8. Laboratory of Translational Cutaneous Medicine, Ingham Institute for Applied Medical Research, Liverpool, New South Wales, Australia

    John W. Frew

  9. Department of Dermatology, Liverpool Hospital, Liverpool, New South Wales, Australia

    John W. Frew

  10. School of Clinical Medicine, University of New South Wales Sydney, Kensington, New South Wales, Australia

    John W. Frew

  11. Department of Dermatology, Polyclinique Courlancy-Bezannes, Reims-Bezannes, France

    Ziad Reguiaï

  12. Probity Medical Research, Waterloo, Ontario, Canada

    Melinda J. Gooderham

  13. SKiN Centre for Dermatology, Peterborough, Ontario, Canada

    Melinda J. Gooderham

  14. Queen’s University, Kingston, Ontario, Canada

    Melinda J. Gooderham

  15. Departments of Dermatology and Medicine, University of Minnesota, Minneapolis, MN, USA

    Noah Goldfarb

  16. Department of Dermatology, University of Minnesota Physicians, Minneapolis, MN, USA

    Noah Goldfarb

  17. Department of Dermatology, Erasmus Medical Center, Rotterdam, Netherlands

    Hessel H. van der Zee

  18. Department of Dermatology, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium

    Veronique del Marmol

  19. Dermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

    Angelo V. Marzano

  20. Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy

    Angelo V. Marzano

  21. Oregon Medical Research Center, Portland, OR, USA

    Benjamin D. Ehst

  22. USA Medical Dermatology Specialists, US Dermatology Partners, Phoenix, AZ, USA

    Lindsay S. Ackerman

  23. Division of Cutaneous Science, Department of Dermatology, Nihon University School of Medicine, Itabashi City, Tokyo, Japan

    Koremasa Hayama

  24. Incyte Corporation, Wilmington, DE, USA

    Chenwei Tian, Jennifer Kelley, Huiling Zhen, Joslyn S. Kirby, Kurt Brown & Leandro L. Santos

  25. Department of Dermatology, Venereology, and Immunology, Universitaetsklinikum Ruppin-Brandenburg, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Neuruppin, Germany

    Christos C. Zouboulis

Authors

  1. Martina L. Porter
  2. Antonio Martorell
  3. Christopher J. Sayed
  4. Falk G. Bechara
  5. Hadar Lev-Tov
  6. Jennifer L. Hsiao
  7. John W. Frew
  8. Ziad Reguiaï
  9. Melinda J. Gooderham
  10. Noah Goldfarb
  11. Hessel H. van der Zee
  12. Veronique del Marmol
  13. Angelo V. Marzano
  14. Benjamin D. Ehst
  15. Lindsay S. Ackerman
  16. Koremasa Hayama
  17. Chenwei Tian
  18. Jennifer Kelley
  19. Huiling Zhen
  20. Joslyn S. Kirby
  21. Kurt Brown
  22. Leandro L. Santos
  23. Christos C. Zouboulis

Corresponding author

Correspondence to Christos C. Zouboulis.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Porter, M.L., Martorell, A., Sayed, C.J. et al. Author Correction: Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials. Nat Med (2026). https://doi.org/10.1038/s41591-026-04747-2

Download citation

  • Published: 21 October 2026

  • Version of record: 21 October 2026

  • DOI: https://doi.org/10.1038/s41591-026-04747-2

来源:Nature Medicine · nature.com